biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 28/2025| 13-10-2025 | Zawarcie umowy z doradcą M&A dla projektu BACTEROMIC

Previous PostRAPORT ESPI 27/2025 | 26-09-2025 | Rozszerzenie współpracy w ramach procesu certyfikacji FDA dla Panelu FAST UNINext PostRAPORT ESPI 29/2025 | 15-10-2025 | Wyniki testów wewnętrznych dla Panelu UNI FAST oraz Panelu PBC, tj. paneli kompatybilnych z oprogramowaniem FAST

0Shares

Related Posts

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

SCOPE FLUIDICS0

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

SCOPE FLUIDICS0

Scope Fluidics Secures Another U.S. Patent for the BACTEROMIC System

SCOPE FLUIDICS0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 316 827,10 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Information clause

Whistleblower Protection

Scope Fluidics 2021 ® All rights reserved